Current approaches, such as targeted therapy using FDA-approved BRAF inhibitors (vemurafenib, dabrafenib, and encorafenib), either alone or in combination with MAPK/ERK kinase inhibitors or immune checkpoint inhibitors (ICIs) [10], as well as other immunotherapy approaches, have improved overall survival in patients with BRAF-mutated melanoma [1,9]. The gene discussed is BRAF; the disease is melanoma.